GILD

Remdesivir

COVID-19 Therapy (Moderate)

Phase 3 (Expanded Access)

Exp Date

TBD

Amp Volatility Score

Catalyst Info & Data Links

TITLE: Remdesivir in Moderate COVID-19

  • ClinicalTrial.gov (NCT04292730): Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment



WHAT IS THE CATALYST EVENT?

  • Submit the full data for publication in the upcoming weeks



WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • TBA



PRIOR DATA/EVENTS



HC updated 6/16/20


#GILD, #remdesivir, #covid19

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon